Floatz logo

Ibandronate

Breast Cancer

Azienda Ospedaliero-Universitaria CareggiSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
59/ 100

Competitive context

849 Active assets in the Breast Cancer cohort.

Asset / SponsorPhaseRating
Darolutamide
Vandana Abramson
Phase 2BBB
Pertuzumab
SWOG Cancer Research Network
Phase 4BB
Palbociclib
Hoffmann-La Roche
Phase 4BB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
Goserelin
TerSera Therapeutics LLC
Phase 4BB

View all 50 →

Same molecule, other indications

Ibandronate is also rated in:

metastatic carcinoma in the boneActive
BBB
Indicative · Phase 4
79 / 100
View asset →
cirrhosis of liverActive
B
Indicative · Phase 4
62 / 100
View asset →
metastatic malignant neoplasmActive
B
Indicative · Phase 3
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →